Fiscal benefits of drugs a priority for cash-strapped countries

By Nick Taylor

- Last updated on GMT

Related tags: Asia pacific, Middle east

Cash-strapped countries are making biopharm consider a product’s fiscal benefits earlier in development, according to INC.

Shifts in global economics mean that countries and companies alike are facing restrictions on spending. In this economic environment biopharm must be ready to answer certain questions when seeking to commercialise a product.

Do we invest in your product if there’s no fiscal benefit compared to the incumbent product? That’s becoming more and more, unofficially, a view that many countries are taking​”, said Geoff Fatzinger, director of regulatory affairs and strategic product development at INC Research.

Fatzinger is responsible for Europe, Asia Pacific and the Middle East and fiscal considerations vary significantly across these regions. For example, emerging countries in Asia Pacific have large populations and finite resources, making them particularly keen to see return on investment.

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Covance Touchless Drug and Device Vigilance Vision

Covance Touchless Drug and Device Vigilance Vision

Covance Patient Safety | 01-Sep-2020 | Data Sheet

Automation tools enable organizations to identify patterns in structured and unstructured data and facilitate automation of the entire product vigilance...

Related suppliers

Follow us


View more